Loading
Interleukin-12 is an immune-stimulating cytokine that caused severe toxicity when injected into the bloodstream in the 1990s and was abandoned. An oncolytic herpes or adenovirus carrying the interleukin-12 gene under a drug-inducible promoter makes it only inside the tumour, keeping exposure local; trials include recurrent glioblastoma.
Systemic interleukin-12 caused severe toxicity in the 1990s and was abandoned. Oncolytic herpes and adenovirus vectors carrying interleukin-12 under regulated or drug-inducible promoters, including trials in recurrent glioblastoma, keep exposure local and measurable. Combining a regulated cytokine payload with checkpoint blockade is a rational path to converting cold tumours.
Shares CG Oncology, Cretostimogene grenadenorepvec, Oncolytic viruses, Bladder & urothelial cancer.
Shares CG Oncology, Cretostimogene grenadenorepvec, Oncolytic viruses, Bladder & urothelial cancer.
Shares CG Oncology, Cretostimogene grenadenorepvec, Oncolytic viruses, Bladder & urothelial cancer.
Shares Vusolimogene oderparepvec, Talimogene laherparepvec, Oncolytic viruses, Melanoma.
Shares Replimune, Vusolimogene oderparepvec, Oncolytic viruses, Melanoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cytokines & engineered cytokines, Cold tumours and the immunosuppressive microenvironment, Melanoma.
Shares Cretostimogene grenadenorepvec, Oncolytic viruses, Bladder & urothelial cancer.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Bladder & urothelial cancer, Immune checkpoint inhibitors.